Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Voir le projet

 44

 TERMINÉ 

Molecular Tools for Nucleic Acid Manipulation for Biological Intervention (MMBio)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combi ...
Voir le projet

 13

 TERMINÉ 

PET Imaging in Drug Design and Development (PET3D)

Date du début: 1 juin 2016, Date de fin: 31 mai 2020,

The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and drug treatment should become more “personalized” and “rationalized”. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and i ...
Voir le projet

 8

 TERMINÉ 

Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet

 26

 TERMINÉ 

Zoonotic Anticipation and Preparedness Initiative (ZAPI)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

Emerging infectious diseases are occurring at increasing frequency in Europe and other regions of the world, having profound impacts on public and/or veterinary health as well as disruptive effects on sector, regional or even global economy. The predominantly zoonotic nature of emerging pathogens calls for a One Health approach uniting the human medical and veterinary fields, dedicated to swiftly ...
Voir le projet

 21

 TERMINÉ 

Combatting Bacterial Resistance in Europe - Carbapenem Resistance (COMBACTE-CARE)

Date du début: 1 mars 2015, Date de fin: 28 févr. 2020,

Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (M ...
Voir le projet

 23

 TERMINÉ 

European Gram Negative Antibacterial Engine (ENABLE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2020,

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, a ...
Voir le projet

 42

 TERMINÉ 

Targeted small-molecule Stabilisation of Protein-Protein Interactions (TASPPI)

Date du début: 1 févr. 2016, Date de fin: 31 janv. 2020,

...to overcome the inherent boundaries between academia and industry and to increase their employability in both areas. To this end we have teamed up in a consortium comprising 5 partners from industry (AstraZeneca, GlaxoSmithKline, UCB, Lead Disocvery Center, Taros Chemicals) and 6 partners from academia (Universities of Dundee, Eindhoven, Leeds, Lille, Prague, and Siena). The scientific objective o ...
Voir le projet

 10

 TERMINÉ 

Combatting Bacterial Resistance in Europe (COMBACTE-NET)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2019,

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are aro ...
Voir le projet

 38

 TERMINÉ 

Big Data in Chemistry (BIGCHEM)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

The advent of the big data era in chemistry and the life sciences requires the development of new computational analysis methods, which are not only of scientific, but also economic relevance. Currently, the international data market already grows six times faster than the entire IT sector, and growth rates further increase. Achieving and sustaining a leadership positions in the big data arena rep ...
Voir le projet

 9

 TERMINÉ 

Accelerated Early staGe drug diScovery (AEGIS)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia.The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cros ...
Voir le projet

 11

 TERMINÉ 

ISOTOPIC LABELING FOR DRUG INNOVATION (ISOTOPICS)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Metabolism and Excretion studies carried out on larger series of drug candidates at an earlier stage of the DDD timeline and evaluation of drug efficacy through better assessment of pharmacokinetic/pharmacodynamic relationships, target engagement and receptor occu ...
Voir le projet

 8

 TERMINÉ 

Advanced XFEL and Synchrotron based Probes of Protein Structure and Dynamics (X-probe)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

This cross-disciplinary Marie Curie Innovative Training Network builds upon the transformative opportunities created by existing X-ray sources and new sources soon to be operative in Europe. These opportunities include using ultrafast X-ray sources to extract time-dependent structural information from proteins; and revolutionary possibilities created by X-ray Free Electron Laser radiation for an e ...
Voir le projet

 9

 TERMINÉ 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Voir le projet

 29

 TERMINÉ 

Exascale Compound Activity Prediction Engine (ExCAPE)

Date du début: 1 sept. 2015, Date de fin: 31 août 2018,

Scalable machine learning of complex models on extreme data will be an important industrial application of exascale computers. In this project, we take the example of predicting compound bioactivity for the pharmaceutical industry, an important sector for Europe for employment, income, and solving the problems of an ageing society. Small scale approaches to machine learning have already been trial ...
Voir le projet

 10

 TERMINÉ 

"FLUOR21 : Synthesis, structure and function of fluorinated systems" (FLUOR21)

Date du début: 1 mars 2014, Date de fin: 28 févr. 2018,

"Organofluorine chemistry has played a significant role in the majority of the spectacular scientific and technological developments of thepast century although this is not widely recognised even by the scientific community. Fluoroorganic molecules are key components in anever increasing number of high-value commercially important products particularly in the life science industries. The use of fl ...
Voir le projet

 9

 TERMINÉ 

Molecular basis of the outer membrane permeability (TRANSLOCATION)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Voir le projet

 28

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet

 34

 TERMINÉ 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet

 26

 TERMINÉ 

Kinetics for Drug Discovery (K4DD) (K4DD)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Voir le projet

 21

 TERMINÉ 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Voir le projet

 17

 TERMINÉ 

Oral biopharmaceutics tools (ORBITO)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Voir le projet

 28

 TERMINÉ 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Voir le projet

 38

 TERMINÉ 

Female Investigators in Nonlinear Optical Nanoscopy - FINON (FINON)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

The aim of this ITN is to take the category of Nonlinear Optical Microscopy (NOM) techniques into the nano-dimension, allowing for label-free three-dimensional (3D), dynamic imaging of macromolecular arrangements and nanostructures by probing inherent higher-order electronic and molecular vibrations with novel detection concepts. Specific S&T objectives are to (A) explore the use of nano-sized sca ...
Voir le projet

 6

 TERMINÉ 

Deciphering inter- and intracellular signalling in schizophrenia (IN-SENS)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

IN-SENS is an interdisciplinary, cutting-edge European industry-academia collaborative effort for a novel training of scientists in molecular psychiatry with the prospect of discovering the biology of schizophrenia and actively promote drug discovery. Mental illnesses are a major burden to patients, relatives, and public health worldwide. IN-SENS therefore aims to profoundly change the academic-in ...
Voir le projet

 16

 TERMINÉ 

Identification and validation of novel pharmaceutical drug targets for cardiovascular disease (CARTARDIS)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The int ...
Voir le projet

 13

 TERMINÉ 

Phylogenetic exploration of medicinal plant diversity (MedPlant)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

The MedPlant network will train young researchers in career enhancing approaches and techniques in biodiversity driven drug lead discovery, complimentary and entrepreneurial skills relevant for work in the pharmaceutical industry, regulatory bodies, NGOs and academia. The aim is to improve the students’ chances of employment and to strengthen Europe's research base through a collaborative training ...
Voir le projet

 10

 TERMINÉ 

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE (DRIVE-AB)

Date du début: 1 oct. 2014, Date de fin: 30 sept. 2017,

Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements ...
Voir le projet

 27

 TERMINÉ 

Recognising Adverse Drug Reactions (WEB-RADR)

Date du début: 1 sept. 2014, Date de fin: 31 août 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet

 20

 TERMINÉ 

BeTheCuRE (BTCURE)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Voir le projet

 41

 TERMINÉ 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Voir le projet

 33

 TERMINÉ 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Voir le projet

 29

 TERMINÉ 

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,

The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet

 30

 TERMINÉ 

Membrane Protein Nanocrystallography (NanoMem)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

Modern structural biology builds upon synergies between lab-bench scale science on the one hand and large scale research infrastructure on the other. NanoMem recognises the transformative opportunities that are created by current X-ray source and detector developments to impact strongly on membrane protein structure, a challenging sub-field of structural biology. We will exploit synchrotron based ...
Voir le projet

 11

 TERMINÉ 

Pushing the Envelope of Nuclear Magnetic Resonance Spectroscopy for Paramagnetic Systems. A Combined Experimental and Theoretical Approach (pNMR)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

A network combining 9 academic research groups and 4 collaborating industrial companies is proposed to train the next generation of PhD students and post-doctoral researchers, in developing and applying novel experimental and theoretical methods in the NMR spectroscopy of systems containing paramagnetic metals. The assembled team, with researchers distributed throughout the EU, will investigate a ...
Voir le projet

 12

 TERMINÉ 

Incorporating real-life clinical data into drug development (GETREAL)

Date du début: 1 oct. 2013, Date de fin: 31 déc. 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Voir le projet

 32

 TERMINÉ 

European Bank for induced pluripotent Stem Cells (EBISC)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet

 30

 TERMINÉ 

Innovative Modelling for Pharmacological Advances through Collaborative Training (IMPACT)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

"This project forms an interdisciplinary collaborative partnership between AstraZeneca (AZ, Sweden) and the University of Warwick (UoW, UK) to train Early Stage Researchers (ESRs) in systems modelling tools and techniques enabling them to perform research projects at the forefront of international pharmacokinetic (PK) and pharmacodynamic (PD) analysis. This project will build upon extremely strong ...
Voir le projet

 2

 TERMINÉ 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Voir le projet

 22

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34